Enveric Biosciences, Inc. (ENVB) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-208.80 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-19.04 vs est $-208.80 (beat +90.9%). 2025: actual $-36.24 vs est $-154.80 (beat +76.6%). Analyst accuracy: 0%.
ENVB Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Enveric Biosciences, Inc. in the past 3 months
EPS Estimates — ENVB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$19.04
vs Est –$208.80
▲ 996.6% off
2025
Actual –$36.24
vs Est –$154.80
▲ 327.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ENVB
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
